Real world evidence of PD-L1, TMB prevalence and efficacy of 1st line chemotherapy in these high or low population for stage IV urothelial cancer - YODO study Real world evidence of PD-L1 prevalence and efficacy of 1st line chemotherapy for stage IV urothelial cancer

By performing validated assay techniques on the FFPE samples, including Ventana PD-L1 (SP263) assay and NGS, PD-L1 expression, histological classification, cancer-immune phenotype, and TMB could be determined. Based on these data, prevalence of the immunogenic biomarkers including PD-L1 expression, TMB and OS, PFS from start of first-line treatment for Stage IV urothelial cancer was assessed.